Xcout Intel
FOSUN PHARMA competitors & alternatives
The 12 closest competitors and alternatives to FOSUN PHARMA among pharmaceuticals companies — ranked by similarity to what FOSUN PHARMA actually does, not by market-cap band.
Subscribe to see FOSUN PHARMA’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About FOSUN PHARMA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
FOSUN PHARMA at a glance
FOSUN PHARMA is a pharmaceuticals company headquartered in China, founded in 1994. It is publicly listed (02196) with a market capitalisation of $7.8B.
Top 12 FOSUN PHARMA competitors
Ranked by semantic similarity — how close each company is to FOSUN PHARMA by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.
Similar pharmaceuticals company
Shanghai Pharmaceuticals Holding Co., Ltd., a diversified investment holding entity established in 1994 and headquartered in Shanghai, China, plays a crucial role in the People's Republic of China's pharmaceutical and healthcare sectors. As a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd., its extensive operations encompass research, development, manufacturing, distribution, and retail of a wide array of products. The company's business model is structured around four principal segments: Production, Distribution, Retail, and an 'Others' category. Within its Production segment, it develops and manufactures a broad portfolio of pharmaceuticals, including chemical and biochemical drugs, traditional Chinese medicines, healthcare solutions, and medical devices. These offerings target diverse therapeutic fields such as oncology, cardiovascular and cerebrovascular conditions, central nervous system disorders, general infections, immunological diseases, digestive and metabolic ailments, and respiratory issues. The company's product range comprises approximately 700 distinct drug varieties. Beyond manufacturing, its Distribution arm is instrumental in providing comprehensive pharmaceutical supply chain solutions. This includes warehousing, logistics, and value-added services for various industry players, from pharmaceutical manufacturers to dispensers like hospitals, other distributors, and retail pharmacies. Furthermore, the company manages an extensive network of retail pharmacies, alongside a burgeoning online drug sales platform. This retail footprint spans approximately 2,000 chain pharmacies across 24 provinces. Its 'Others' segment encompasses a variety of support and innovative services, such as consulting, asset management, clinical trial coordination, medical assistance programs, educational initiatives for healthcare professionals and patients, e-prescription management systems, and the development of remote and cloud hospital technologies.
Similar pharmaceuticals company
Roche is a healthcare company that develops and provides pharmaceuticals and diagnostic solutions. It focuses on preventing, diagnosing, and treating severe health conditions such as cancer, cardiovascular-metabolic diseases, and neurological disorders for patients worldwide.
Similar pharmaceuticals company
Joincare Pharmaceutical Group Industry Co., Ltd. is a Chinese enterprise primarily focused on the comprehensive process of researching, developing, producing, and commercializing pharmaceutical and healthcare products within China. The company boasts a broad pharmaceutical portfolio that includes both Western chemical drug preparations, addressing conditions such as respiratory, gastrointestinal, anti-infection, gonadotropic, and psychiatric disorders, as well as traditional Chinese medicines (TCM), with offerings for anti-tumor and cold relief. Beyond finished drugs, Joincare supplies chemical active pharmaceutical ingredients (APIs) and intermediates. Its operations also extend into the diagnostics sector, where it provides specialized reagents and equipment, such as an autoimmunity multiple detection platform and an IgM diagnostic kit. Furthermore, the company markets a range of health and wellness products, exemplified by American ginseng tea and Jingxin menocare essence. Joincare diversifies its business by engaging in the wholesale and retail of personal care items, including skincare products, cosmetics, and various other essential goods. Its products are available in diverse formats, such as hormone tablets, oral liquid formulations, and standard tablets. Established in 1992, Joincare Pharmaceutical Group maintains its principal offices in Shenzhen, China.
Similar pharmaceuticals company
Livzon Pharmaceutical Group Inc., founded in Zhuhai, China, in 1985, is a prominent enterprise dedicated to the research, development, manufacturing, and global commercialization of a wide range of pharmaceutical products, including finished drugs, active pharmaceutical ingredients (APIs), and intermediate chemical compounds. The company's extensive therapeutic portfolio features numerous specialized medications, such as Ilaprazole enteric coated tablets for treating duodenal ulcers and reflux esophagitis, and Laprazole sodium injections designed to manage peptic ulcer hemorrhage. Other key pharmaceutical offerings include Leuprorelin Acetate Microspheres for injection, Urofollitropin injections for anovulation, Perospirone Hydrochloride for schizophrenia treatment, Anti-viral Granules for combating upper respiratory tract infections and influenza, and Shenqi Fuzheng Injection, which addresses general weakness, fatigue, sweating, and vertigo, and is also applied in managing symptoms for lung and stomach cancer patients. Beyond therapeutics, Livzon also excels in producing diagnostic reagents. Its diagnostic kits include those for detecting IgM/IgG antibodies to coronavirus, nucleic acid test kits for human immunodeficiency virus type 1, antinuclear antibody tests, interferon-gamma release assays, and rapid tests for Mycoplasma pneumoniae IgM antibodies. Furthermore, the company's comprehensive product line encompasses biochemical drugs, microbiological preparations, biologics, traditional Chinese medicinal preparations, pharmaceutical raw materials, and antibiotics.
Similar pharmaceuticals company
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company has a business collaboration with the Sirtex Group agreement to enable collaboration on research and development of pharmaceutical products. The company has a strategic partnership with the University of Hong Kong for the research and development of drugs in the field of anti-infection and the industrialization of the research results. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.
Similar pharmaceuticals company
Roche Singapore Pte Ltd researches and develops pharmaceuticals and diagnostic solutions to detect, treat, and monitor various diseases. The company utilizes data-based insights to support healthcare professionals and improve patient health outcomes.
Similar pharmaceuticals company
Tonghua Dongbao Pharmaceutical Co., Ltd. is a Chinese enterprise primarily engaged in the research, development, manufacturing, and commercialization of pharmaceutical products. These therapeutics are designed to address diabetes and various cardiovascular conditions within the Chinese market. Its operations are structured across two distinct divisions: pharmaceuticals and building materials. The company's extensive pharmaceutical portfolio features prominent insulin analogues, including insulin glargine, insulin aspart, and insulin lispro. Furthermore, it offers a range of antidiabetic medications, oral hypoglycemic drugs, and medical devices such as Gan Shulin pens and blood glucose meters. Tonghua Dongbao also maintains a strategic partnership with Adocia. Established in 1985, the company is headquartered in Tonghua, China.
Similar pharmaceuticals company
Santen Pharmaceutical Co., Ltd. is a global enterprise engaged in the research, development, manufacturing, and marketing of both pharmaceutical products and medical devices. The company's primary focus lies in ophthalmic solutions, addressing a variety of eye conditions. Its pipeline for glaucoma and ocular hypertension includes several key assets: DE-111, currently in Phase III clinical trials; DE-117, available for sale in Japan; DE-126, progressing through Phase IIb trials; DE-128, which is on the market in Europe and undergoing Phase II/III trials in the United States; and DE-130A, also in Phase III development. Beyond glaucoma, Santen's offerings extend to other ocular ailments. It provides DE-114A for allergic conjunctivitis and DE-076C for vernal keratoconjunctivitis. Furthermore, DE-109 is in Phase III clinical trials for the treatment of uveitis. The company is also active in addressing myopia with DE-127, currently in Phase II/III trials in Japan and Phase III in other Asian markets, alongside STN1013400, which is in Phase I trials. For dry eye, Santen offers DE-089C, which has successfully concluded its Phase III clinical trials. In addition to its prescription portfolio, the company produces and sells various over-the-counter (OTC) pharmaceutical products. Founded in 1890 under the name Santendo Pharmaceutical Co., Ltd., the company rebranded to its current name, Santen Pharmaceutical Co., Ltd., in 1958. It is headquartered in Osaka, Japan.
Similar pharmaceuticals company
Beroni Group Limited, established in 2014 and based in Sydney, Australia, is a global enterprise operating in China, Australia, the United States, and Japan. The company specializes in the creation and distribution of a diverse portfolio of health and wellness products. Its offerings span several key areas: Smoking Harm Reduction: This includes products like NicoBloc, designed to aid in smoking cessation. Environmental Quality: Beroni provides air purification systems, such as Fogibloc, and water filtration solutions under the Olansi brand. Health and Wellness: The company supplies a variety of health supplements and also markets cosmetic products, including V show rejuvenation liquids and various hyaluronic acid and avocado-based intensive treatment masks. Stem cell-derived cosmetic products are also part of its range. Diagnostic Tools: Beroni is active in the diagnostics field, offering detection kits for viruses like the SARS-CoV-2 IgG/IgM antibody kit for COVID-19, as well as the CII-ArboViroPlex rRT-PCR assay, which identifies arboviruses such as Zika, Dengue, Chikungunya, and West Nile. Beyond product sales, Beroni Group is heavily invested in research and development. Its R&D efforts focus on discovering and developing novel pharmaceutical drugs, conducting clinical trials, and advancing anti-cancer therapies. The company also provides services in gene detection and diagnosis, infectious disease diagnostics, and offers cell therapies for both cancer treatment and anti-aging applications. Furthermore, Beroni manages an e-commerce platform dedicated to pharmaceutical and healthcare products.
Similar pharmaceuticals company
Johnson & Johnson researches, develops, and delivers innovative medicines, therapies, and medical technology devices. The company focuses on healthcare areas such as oncology, neuroscience, immunology, cardiovascular diseases, orthopaedics, and surgery to serve patients globally.
Biotechnology
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of FOSUN PHARMA and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for FOSUN PHARMAand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →